胰腺癌的综合治疗进展  

Advances in the comprehensive treatment of pancreatic cancer

作　　者：郭勇 龚建平[2] 李培志[2] Guo Yong;Gong Jianping;Li Peizhi(Department of Hepatobiliary Surgery,Changshou District People's Hospital,Chongqing 401220,China;Department of Hepatobiliary Surgery,the Second Affiliated Hospital of Chongqing Medical University Chongqing 400010,China)

机构地区：[1]重庆市长寿区人民医院肝胆外科,401220 [2]重庆医科大学附属第二医院肝胆外科,400010

出　　处：《国际外科学杂志》2021年第9期638-643,共6页International Journal of Surgery

摘　　要：胰腺癌是一种高度恶性的消化系统肿瘤,目前其发病率及病死率仍居高不下。手术目前仍是唯一可能治愈胰腺癌的方式,对于可切除胰腺癌,"动脉优先"入路和"胰腺全系膜切除"等手术原则提高了局部的根治性,并减少了局部肿瘤的复发率。对于交界性可切除胰腺癌和局部进展期胰腺癌,可先行新辅助化疗后再考虑手术切除。虽然目前并没有针对胰腺癌的靶向及免疫治疗药物,但相关单克隆抗体的临床研究一直在进行中。嵌合抗原受体T细胞治疗及不可逆电穿孔作为新兴的治疗方式,在胰腺癌中的治疗中也逐渐占有一席之地。本文将对胰腺癌的综合治疗现状及进展作一综述。Pancreatic cancer is one of the most malignant digestive cancer with high morbidity and mortality.Surgical treatment is considered the only way to cure pancreatic cancer.For resectable pancreatic cancer,the principles of"artery-frst approach"and"systematic mesopancreas dissection"have improved the increase the local radicality and reduce the local recurrence rate.For borderline resectable pancreatic cancer and locally advanced pancreatic cancer,neoadjuvant chemotherapy can be used before surgical resection.Although there are no targeted and immunotherapeutic drugs for pancreatic cancer,clinical studies on monoclonal antibodies are ongoing.Chimeric antigen receptor T cell therapy and irreversible electroporation are emerging therapies in the treatment of pancreatic cancer.In the present study,the status and progress of comprehensive treatment for pancreatic cancer are reviewed.

关 键 词：胰腺肿瘤 治疗学 进展 

分 类 号：R735.9[医药卫生—肿瘤]